Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
AACR 2018 Annual Report.
Ahn J, et al. Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control. 2012;23:399–404.
Islami F, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31–54.
Gapstur SM, et al. A blueprint for the primary prevention of cancer: targeting established, modifiable risk factors. CA Cancer J Clin. 2018;68:446–70.
Jamal A, et al. Current cigarette smoking among adults—United States 2016. MMWR Morb Mortal Wkly Rep. 2018;67:53–9.
Neri A, et al. Radon control activities for lung cancer prevention in National Comprehensive Cancer Control Program Plans, 2005–2011. Prevent Chronic Dis. 2013;10:120337.
Lehmann U, Bartels S. Liquid biopsy in tumor diagnostics. Pathologe. 2019; https://doi.org/10.1007/s00292-019-0604-5.
Stobiecka M, Ratajczak K, Jakiela S. Toward early cancer detection: focus on biosensing systems and biosensors for an anti-apoptotic protein survivin and survivin mRNA. Biosens Bioelectron. 2019;137:58–71. https://doi.org/10.1016/j.bios.2019.04.060. [Epub ahead of print].
Hung KF, et al. MicroRNA-31 upregulation predicts increased risk of progression of oral potentially malignant disorder. Oral Oncol. 2016;53:42–7.
Sharma DC. Salivary bacteria linked to oral cancers. Lancet Oncol. 2005;6:547.
Herrero R, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772–83.
Sohrabi M, Nair RG, Samaranayake LP, et al. The yield and quality of cellular and bacterial DNA extracts from human oral rinse samples are variably affected by the cell lysis methodology. J Microbiol Methods. 2016;122:64–72.
Fadhil RS, Wei MQ, Nikolarakos D, Good D, Nair RG. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic biomarkers for head and neck squamous cell carcinoma. PLoS One. 2020;15(3):e0221779. https://doi.org/10.1371/journal.pone.0221779. eCollection 2020.
Fadhil R, Nair RG, Nikolarakos D, Wei M. Next Generation Sequencing Identifies Novel Diagnostic Biomarkers for Head and Neck Squamous Cell Carcinoma. Oral Cancer. 2019; https://doi.org/10.1007/s41548-019-00019-5.
Tsimberidou AM, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019.
Al-Samadi A, et al. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. Exp Cell Res. 2019;383:111508.
Wang Y, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck carcinomas. Sci Transl Med. 2015;7:293ra104.
Nor JE, Gutkind JS. Head and Neck Cancer in the new era of precision medicine. J Dent Res. 2018;97:601–2.
Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–7.
Polverini PJ, et al. Precision therapy of head and neck squamous cell carcinoma. J Dent Res. 2018;97:614–21.
Bachour P, Sonis ST. Predicting the risk of mucositis associated with cytotoxic cancer treatment regimens: rationale, complexity and challenges. Curr Opin Support Palliat Care. 2018;12:1998–210.